However, since clinical trials based on VEGF-targeted anti-angiogenic therapies of bladder cancer have not given satisfactory results [21], there is a need to search for other mediators of both pro-angiogenic and anti-cytotoxic effects of HIFs and Nrf2. This evidence concerns the gene VEGFA and urinary bladder cancer.